AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Other Vaccines & Immune Therapies by Quarter
Other Vaccines & Immune Therapies — Worldwide YoY CER (%) (%)
AstraZeneca Other Vaccines & Immune Therapies: -34.0% in Q2 2026.
Latest, Q2 2026
-34.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q1 2024
Sources
4
Documents cited below
Where the Q2 2026 figure comes from
“|| Other ID | | 34 | | ( 31 ) | | ( 34 ) | | ( 1 ) | | 73 | | 30 | | ( 20 ) | | ( 26 ) | | 1 | | 78 | | 69 | | 4 | | ( 68 ) | | ( 66 )”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Vaccines & Immune Therapies — Worldwide YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -34.0% | – | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -53.0% | +40.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -93.0% | -13.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -80.0% | – | Form 6-K FY2024Q1 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Other Vaccines & Immune Therapies (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-vi-world-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.